Can gold therapy be used more safely in rheumatoid arthritis? Adverse drug reactions are more likely in patients with nodular disease, independent of HLA-DR3 status

Journal of Rheumatology

Volumn 31, Issue 10, 2004, Pages 1903-1905

  Shah, Preeti ^a   Griffith, Sian M ^a   Shadforth, Michael F ^a   Fisher, June ^a   Dawes, Peter T ^a   Poulton, Kay V ^a   Thomson, Wendy ^a   Ollier, William E R ^b   Mattey, Derek L ^a  

^a Staffordshire Rheumatology Centre   (United Kingdom)

^b Stopford Building   (United Kingdom)

Author keywords

Adverse reactions; Gold therapy; HLA; Nodules; Rheumatoid arthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUROTHIOMALATE; GOLD SALT; HLA DR ANTIGEN; HLA DR3 ANTIGEN; RHEUMATOID FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEREDITY; HLA TYPING; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MCNEMAR TEST; PRIORITY JOURNAL; PROTEINURIA; RHEUMATOID ARTHRITIS; SKIN NODULE; THROMBOCYTOPENIA;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; GOLD SODIUM THIOMALATE; HLA-DR3 ANTIGEN; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; REGRESSION ANALYSIS; RHEUMATOID NODULE; THROMBOCYTOPENIA;

EID: 5044221751     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Husain Z, Runge LA. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine and levamisole in patients with rheumatoid arthritis. J Rheumatol 1980;7:825-30.
2. Panayi GS, Wooley P, Batchelor JR. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. BMJ 1978;2:1326-8.
3. Wooley PH, Griffin J, Panayi GS, Batchelor JR, Welsh KI, Gibson TJ. HLA-DR antigens and toxic reaction to sodium aurothiomalate and d-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980;303:300-2.
4. Gran TJ, Husby G, Thorsby E. HLA antigens and gold toxicity. Ann Rheum Dis 1983;42:63-6.
5. van Riel PLCM, Reekers P, van Putte LBA, Gribhau FWJ. Association of HLA antigens, toxic reactions and therapeutic response to auranofin and aurothioglucose in patients with rheumatoid arthritis. Tissue Antigens 1983;22:194-9.
6. Scherak O, Smolen JS, Mayr WR, Mayrhofer F, Kolarz G, Thumb NJ. HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis. J Rheumatol 1984;11:610-4.
7. Singal DP, Reid B, Green D, D'Souza M, Bensen WG, Buchanan WW. Polymorphism of major histocompatibility complex extended haplotypes bearing HLA-DR3 in patients with rheumatoid arthritis and gold-induced thrombocytopenia or proteinuria. Ann Rheum Dis 1990;49:582-6.
8. Sakkas LI, Chikanza IC, Vaughan RW, Welsh KI, Panayi GS. Gold induced nephropathy in rheumatoid arthritis. Ann Rheum Dis 1993;52:300-1.
9. Mattey DL, Dawes PT, Gonzalez-Gay MA, et al. HLA-DRB1 alleles encoding an aspartic acid at position 70 protect against development of rheumatoid arthritis. J Rheumatol 2001;28;232-9.
10. Weyand CM, Xie C, Goronzy JJ. Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J Clin Invest 1992;89:2033-9.
11. Perdriger A, Châles G, Semana G, et al. Role of HLA-DR-DR and DR-DQ associations in the expression of extraarticular manifestations and-rheumatoid factor in rheumatoid arthritis. J Rheumatol 1997;24:1272-6.
12. Mattey DL, Dawes PT, Fisher J, et al. Nodular disease in rheumatoid arthritis: Association with cigarette smoking and HLA-DRB1/TNF gene interaction. J Rheumatol 2002;29:2313-8.